Short answer
ANGIODYNAMICS INC (ANGO) filed its Q3 2025 10-Q quarterly report on Oct 2, 2025 for the quarter ended Aug 31, 2025. Quarterly revenue was $76M (up 12.2% year over year) with net income of −$11M.
Q3 2025 key financials · XBRL
- Revenue
- $76M
- +12.2% YoY
- Net income
- −$11M
- +14.8% YoY
- Operating margin
- -14.1%
- Gross margin
- 55.3%
- EPS (diluted)
- −$0.26
- +16.1% YoY
Source: XBRL data from the ANGIODYNAMICS INC (ANGO) Q3 2025 10-Q on SEC EDGAR. USD.
ANGIODYNAMICS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $75.7M, up 12.2% YoY from $67.5M
- Gross margin 55.3% vs 54.4%; Med Tech margin 62.2% vs 63.3%
- Med Tech best segment, revenue $35.3M, up 26.1%; thrombus platform sales increased $3.2M
- Cash $38.8M vs $55.9M; operating cash outflow $15.9M vs $18.3M
- Headwinds: tariffs reduced gross margin $1.7M; supply chain, labor, inflation and raw-material risks ongoing
Risk Factors
- No risk-factors section provided; excerpt contains Items 2–6 only
- No newly added or materially updated risk identified in the supplied text
- Employee-tax withholding repurchases: 54,406 shares purchased at average $9.19
- Repurchase authorization: up to $15.0 million, with no program purchases during the quarter
- No defaults on senior securities, mine-safety disclosures, or insider trading arrangements reported
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANGIODYNAMICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.